SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

IMV: In Advanced Recurrent Ovarian Cancer, Maveropepimut-S Associated With CPA Demonstrates Durable Clinical Benefit Exceeding 12 Mos With Limited Adverse Events >IMV.T

IMV: In Advanced Recurrent Ovarian Cancer, Maveropepimut-S Associated With CPA Demonstrates Durable Clinical Benefit Exceeding 12 Mos With Limited Adverse Events >IMV.T

· 03/17/2021 07:06

Please log in to view news